Belzutifan for teens with certain solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests an oral drug called belzutifan in adolescents with specific types of solid tumors, such as pheochromocytoma/paraganglioma, wild-type gastrointestinal stromal tumors, or tumors linked to von Hippel-Lindau disease. It aims to see if the drug can shrink or control these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adolescent (teenager) with one of these conditions: pheochromocytoma/paraganglioma that cannot be removed by surgery, wild-type gastrointestinal stromal tumors, or tumors related to von Hippel-Lindau disease.
- Your tumor must be measurable on scans (using the RECIST 1.1 criteria).
- You cannot have received prior treatment with any drug like belzutifan (including other HIF-2α inhibitors).
- You must not have certain lung, heart, or immune problems, such as low oxygen levels, uncontrolled heart disease, or a history of HIV.
- You cannot have another cancer that is growing or needed treatment in the past 2 years, unless it is a specific minor skin cancer or similar.
- You must not have active brain metastases, an active infection requiring systemic therapy, or have had an organ or stem cell transplant within the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
This trial tests the drug belzutifan (a pill taken by mouth) in people with VHL syndrome who have kidney or other VHL-related tumors that are growing or can be measured. The study looks at how well belzutifan works in real-world conditions and whether certain genetic factors affect how the drug works.
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
This study tests a daily pill called belzutifan for people with a rare type of gynecologic cancer (clear cell carcinoma) that has come back or not gone away after standard treatments. The drug works by targeting a protein that helps tumors grow when oxygen levels are low.
Hear when a new Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.